277 related articles for article (PubMed ID: 31541927)
1. Characterization of a head and neck cancer-derived cell line panel confirms the distinct TP53-proficient copy number-silent subclass.
van Harten AM; Poell JB; Buijze M; Brink A; Wells SI; René Leemans C; Wolthuis RMF; Brakenhoff RH
Oral Oncol; 2019 Nov; 98():53-61. PubMed ID: 31541927
[TBL] [Abstract][Full Text] [Related]
2. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
[TBL] [Abstract][Full Text] [Related]
3. Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing.
Chung CH; Guthrie VB; Masica DL; Tokheim C; Kang H; Richmon J; Agrawal N; Fakhry C; Quon H; Subramaniam RM; Zuo Z; Seiwert T; Chalmers ZR; Frampton GM; Ali SM; Yelensky R; Stephens PJ; Miller VA; Karchin R; Bishop JA
Ann Oncol; 2015 Jun; 26(6):1216-1223. PubMed ID: 25712460
[TBL] [Abstract][Full Text] [Related]
4. Association of TP53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck Cancer.
Deneka AY; Baca Y; Serebriiskii IG; Nicolas E; Parker MI; Nguyen TT; Xiu J; Korn WM; Demeure MJ; Wise-Draper T; Sukari A; Burtness B; Golemis EA
Clin Cancer Res; 2022 May; 28(9):1925-1937. PubMed ID: 35491653
[TBL] [Abstract][Full Text] [Related]
5. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.
Seiwert TY; Zuo Z; Keck MK; Khattri A; Pedamallu CS; Stricker T; Brown C; Pugh TJ; Stojanov P; Cho J; Lawrence MS; Getz G; Brägelmann J; DeBoer R; Weichselbaum RR; Langerman A; Portugal L; Blair E; Stenson K; Lingen MW; Cohen EE; Vokes EE; White KP; Hammerman PS
Clin Cancer Res; 2015 Feb; 21(3):632-41. PubMed ID: 25056374
[TBL] [Abstract][Full Text] [Related]
6. The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.
Martin D; Abba MC; Molinolo AA; Vitale-Cross L; Wang Z; Zaida M; Delic NC; Samuels Y; Lyons JG; Gutkind JS
Oncotarget; 2014 Oct; 5(19):8906-23. PubMed ID: 25275298
[TBL] [Abstract][Full Text] [Related]
7. Generation and molecular characterization of head and neck squamous cell lines of fanconi anemia patients.
van Zeeburg HJ; Snijders PJ; Pals G; Hermsen MA; Rooimans MA; Bagby G; Soulier J; Gluckman E; Wennerberg J; Leemans CR; Joenje H; Brakenhoff RH
Cancer Res; 2005 Feb; 65(4):1271-6. PubMed ID: 15735012
[TBL] [Abstract][Full Text] [Related]
8. FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner.
Pifer PM; Yang L; Kumar M; Xie T; Frederick M; Hefner A; Beadle B; Molkentine D; Molkentine J; Dhawan A; Abdelhakiem M; Osman AA; Leibowitz BJ; Myers JN; Pickering CR; Sandulache VC; Heymach J; Skinner HD
Clin Cancer Res; 2024 Jan; 30(1):187-197. PubMed ID: 37819945
[TBL] [Abstract][Full Text] [Related]
9.
Cao CH; Liu R; Lin XR; Luo JQ; Cao LJ; Zhang QJ; Lin SR; Geng L; Sun ZY; Ye SK; Yu ZY; Shi Y; Xia X
Int J Biol Sci; 2021; 17(7):1744-1756. PubMed ID: 33994859
[TBL] [Abstract][Full Text] [Related]
10. TP53 mutations in head and neck cancer.
Nathan CA; Khandelwal AR; Wolf GT; Rodrigo JP; Mäkitie AA; Saba NF; Forastiere AA; Bradford CR; Ferlito A
Mol Carcinog; 2022 Apr; 61(4):385-391. PubMed ID: 35218075
[TBL] [Abstract][Full Text] [Related]
11. Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma.
Lim SM; Cho SH; Hwang IG; Choi JW; Chang H; Ahn MJ; Park KU; Kim JW; Ko YH; Ahn HK; Cho BC; Nam BH; Chun SH; Hong JH; Kwon JH; Choi JG; Kang EJ; Yun T; Lee KW; Kim JH; Kim JS; Lee HW; Kim MK; Jung D; Kim JE; Keam B; Yun HJ; Kim S; Kim HR
Cancer Res Treat; 2019 Jan; 51(1):300-312. PubMed ID: 29747488
[TBL] [Abstract][Full Text] [Related]
12. Distinct effects of alcohol consumption and smoking on genetic alterations in head and neck carcinoma.
Urashima M; Hama T; Suda T; Suzuki Y; Ikegami M; Sakanashi C; Akutsu T; Amagaya S; Horiuchi K; Imai Y; Mezawa H; Noya M; Nakashima A; Mafune A; Kato T; Kojima H
PLoS One; 2013; 8(11):e80828. PubMed ID: 24278325
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus-driven repression of NRF2 signalling confers chemo-radio sensitivity and predicts prognosis in head and neck squamous cell carcinoma.
Ramesh PS; Bovilla VR; Swamy VH; Manoli NN; Dasegowda KB; Siddegowda SM; Chandrashekarappa S; Somasundara VM; Kabekkodu SP; Rajesh R; Devegowda D; Thimmulappa RK
Free Radic Biol Med; 2023 Aug; 205():234-243. PubMed ID: 37328018
[TBL] [Abstract][Full Text] [Related]
14. Attenuated TRAF3 Fosters Activation of Alternative NF-κB and Reduced Expression of Antiviral Interferon, TP53, and RB to Promote HPV-Positive Head and Neck Cancers.
Zhang J; Chen T; Yang X; Cheng H; Späth SS; Clavijo PE; Chen J; Silvin C; Issaeva N; Su X; Yarbrough WG; Annunziata CM; Chen Z; Van Waes C
Cancer Res; 2018 Aug; 78(16):4613-4626. PubMed ID: 29921694
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
[TBL] [Abstract][Full Text] [Related]
16. Rapalogs induce non-apoptotic, autophagy-dependent cell death in HPV-negative TP53 mutant head and neck squamous cell carcinoma.
Alam MM; Marin Fermin J; Spiller PT; Burnett C; Rong X; Moore-Medlin T; Maxwell CO; Khandelwal AR; Nathan CO
Mol Carcinog; 2022 Jan; 61(1):33-44. PubMed ID: 34598317
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus associated XPF deficiency increases alternative end joining and cisplatin sensitivity in head and neck squamous cell carcinoma.
Zuo N; Ma L; Liu T; Hu W; Luo Y; Meng H; Ren Q; Deng Y; Wei L; Liu Q
Oral Oncol; 2023 May; 140():106367. PubMed ID: 36996606
[TBL] [Abstract][Full Text] [Related]
18. Expression of SESN1, UHRF1BP1, and miR-377-3p as prognostic markers in mutated TP53 squamous cell carcinoma of the head and neck.
El Baroudi M; Machiels JP; Schmitz S
Cancer Biol Ther; 2017 Oct; 18(10):775-782. PubMed ID: 28886272
[TBL] [Abstract][Full Text] [Related]
19. TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response.
Zhou G; Liu Z; Myers JN
J Cell Biochem; 2016 Dec; 117(12):2682-2692. PubMed ID: 27166782
[TBL] [Abstract][Full Text] [Related]
20. BCCIPβ facilitates p53 ubiquitination via binding with E6 protein in high-risk HPV positive head and neck squamous cell carcinoma.
Wang F; Wang J; Wang J; Zhang L; Fu H; Li J; Tian T; Zuo J; Lv W; Ma X
Biochem Biophys Res Commun; 2020 Aug; 529(3):685-691. PubMed ID: 32736693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
